4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

4 - GenMark Diagnostics, Inc. (0001487371) (Issuer)

BTIG downgraded GenMark Diagnostics from Buy to Neutral

Cowen & Co. downgraded GenMark Diagnostics from Outperform to Market Perform and set a new price target of $24.05 from $23.00 previously

Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

Canaccord Genuity downgraded GenMark Diagnostics from Buy to Hold

William Blair downgraded GenMark Diagnostics from Outperform to Market Perform

Needham & Company LLC downgraded GenMark Diagnostics from Buy to Hold

Canaccord Genuity reiterated coverage of GenMark Diagnostics with a rating of Buy and set a new price target of $24.00 from $22.00 previously

Jersey City, New Jersey, Oct. 13, 2021 (GLOBE NEWSWIRE) -- Verified Market Research recently published a report, "Gene Panel Market" By Technique (Amplicon-Based Approach, Hybridization-Based Approach), By Design (Predesigned Gene Panels, Customized Gene Panels), By Application (Pharmacogenetics, Diagnosis of Congenital Disorders, Cancer Risk Assessment, Others), and By Geography. According to Verified Market Research, the Global Gene Panel Market size was valued at USD 1.70 Billion in 2020 and is projected to reach USD 8.22 Billion by 2028, growing at a CAGR of 21.36% from 2021 to 2028. Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample/?rid=29123 Browse in-de

Basel, 25 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that it has commenced a cash tender offer for all of the outstanding shares of common stock of GenMark Diagnostics, Inc. (NASDAQ: GNMK) at a price of $24.05 per share. The tender offer is being made pursuant to the previously announced merger agreement dated as of March 12, 2021 among Roche Holdings, Inc., an indirect wholly owned subsidiary of Roche Holding Ltd, Geronimo Acquisition Corp., a wholly owned subsidiary of Roche Holdings, Inc., and GenMark. The tender offer period will expire at 12:00 midnight, Eastern Time, at the end of the day on Wednesday, April 21, 2021, unless the offer is extended. Roche

Roche to acquire GenMark Diagnostics for US$ 24.05 per share with the expectation to close in the 2nd quarter of 2021GenMark provides molecular diagnostic tests that are designed to detect multiple pathogens from a single patient sampleGenMark’s ePlex platform delivers rapid and actionable results so clinicians can determine the cause of infection and the most effective treatment, potentially saving lives and alleviating the healthcare burden. The addition of GenMark’s proprietary multiplex technology complements Roche’s diagnostic offering, addressing a broad range of infectious disease testing needs, including respiratory and bloodstream infections              Basel, 15 March 2021 - Roc

CARLSBAD, Calif., Feb. 25, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the fiscal year and quarter ended December 31, 2020. Full Year 2020 Financial Highlights Total revenue of $171.6 million, an increase of 95% over 2019 ePlex® revenue of $152.6 million, an increase of 155% over 2019 Gross margin of 40%, compared to 32% in 2019Cash and investments were $128.2 million as of December 31, 2020 Delivered $6.1 million in positive cash flows from operating activities

CARLSBAD, Calif., Feb. 22, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that its ePlex Respiratory Pathogen Panel 2 (RP2) is predicted to detect known SARS-CoV-2 variants currently in circulation. As the COVID-19 pandemic continues to evolve, GenMark is routinely monitoring publicly available databases for new SARS-CoV-2 strains and variants and conducting bioinformatic analyses to determine if the mutations present in the viral genome would impact detection of these variants on the ePlex RP2 Panel. The recently identified SARS-CoV-2 variant strains include multiple mutat

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in the upcoming Cowen 41st Annual Health Care Conference. GenMark’s management team is scheduled to present in a virtual setting on Monday, March 1st, 2021 at 2:00 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com ABOUT GENMARKGenMark Diagnostics (NASDAQ: GNMK) is a leading provider of multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality metrics, and redu

CARLSBAD, Calif., Feb. 16, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced today the publication of a manuscript in Frontiers in Cellular and Infection Microbiology that highlights strong performance and the potential clinical impact of the ePlex Blood Culture Identification (BCID) Panels. The study, “Evaluation of Microbiological Performance and the Potential Clinical Impact of the ePlex® Blood Culture Identification Panels for the Rapid Diagnosis of Bacteremia and Fungemia,” looked prospectively at the identification of pathogens and antimicrobial resistance genes, as well as retr

CARLSBAD, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its fourth quarter and full year earnings results after market close on Thursday, February 25, 2021. Management will hold a conference call to review the company's financial performance starting at 4:30 p.m. ET on the same day. The conference call will be concurrently webcast. The link to the webcast will be available on the GenMark Diagnostics, Inc. website at www.genmarkdx.com under the investor relations section and will be archived for future reference. To listen to the conference call, please dial (877) 312-5847 (US/Canada) or (253) 237-1154 (Internati

CARLSBAD, Calif., Jan. 11, 2021 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary operational and financial results for the year ended December 31, 2020. Financial Highlights Total revenue for 2020 is expected to be approximately $171 million, representing an increase of approximately 95% over 2019 ePlex® revenue for the full year 2020 is expected to be approximately $152 million, an increase of 155% over 2019 Total revenue for the fourth quarter of 2020 is expected to be approximately $50 million, representing an increase of 84% over the fourth quarter of 2019 ePlex re

CARLSBAD, Calif., Dec. 28, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences. GenMark’s management is scheduled to present at the 39th Annual J.P. Morgan Healthcare Conference in a virtual setting on Tuesday, January 12th, 2021 at 5:20 p.m. ET. Interested parties can access the live and archived webcast at ir.genmarkdx.com. GenMark’s management is also scheduled to present at the 23rd Annual Needham Growth Conference in a virtual setting on Thursday, January 14, 2021 at 5:0

SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13D - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G - GenMark Diagnostics, Inc. (0001487371) (Subject)

SC 13G/A - GenMark Diagnostics, Inc. (0001487371) (Subject)

15-12B - GenMark Diagnostics, Inc. (0001487371) (Filer)

EFFECT - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)

S-8 POS - GenMark Diagnostics, Inc. (0001487371) (Filer)